MaxCyte, Inc. (MXCT) Misses Q2 EPS by 2c

MaxCyte, Inc. (NASDAQ: MXCT) reported Q2 EPS of ($0.12), $0.02 worse than the analyst estimate of ($0.10). Revenue for the quarter came in at $8.5 million versus the consensus estimate of $9.63 million.

For earnings history and earnings-related data on MaxCyte, Inc. (MXCT) click here.

You May Also Be Interested In

• Chevron signed an agreement with Iraq's Basra Oil Company to advance commercial negotiations for West Qurna 2
• DBV Technologies refreshes ATM program with $150M ADS offering
• DWS Municipal Income Trust sets November 2026 liquidation timeline